Nuvasive Inc (NUVA) 61.57 $NUVA
Genomic Health to Offer Epic Science's AR-V7 test, Shares Up
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:28AM CDT
The availability of the AR-V7 serves as a further development to Genomic Health's (GHDX) recently launched Oncotype SEQ Liquid Select, a next-generation, liquid biopsy test.
ICUI: 115.74 (+0.74), GWPH: 96.35 (+1.52), NUVA: 61.57 (+0.75), GHDX: 27.91 (-0.21)
Walgreen Boots: Q3 a Mixed Bag, Achieves $1B in Synergy
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:09AM CDT
In Jun 2016, Walgreens Boots (WBA) was successful in achieving its target of at least $1 billion in combined net synergies from the Alliance Boots deal in fiscal 2016.
ICUI: 115.74 (+0.74), WBA: 82.01 (+0.21), GWPH: 96.35 (+1.52), NUVA: 61.57 (+0.75)
Henry Schein Rides High on Strategic Buyouts, Price Hurts
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:58AM CDT
Henry Schein's (HSIC) latest acquisition development includes the completion of its takeover of 50% interest in J Morita's subsidiary, One Piece Corp.
BSX: 23.77 (-0.13), ICUI: 115.74 (+0.74), HSIC: 181.78 (+1.06), NUVA: 61.57 (+0.75)
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 42.12 (+0.23), JNJ: 122.93 (+0.08), ZBH: 125.08 (+0.19), LDRH: 37.00 (+0.03), MDT: 88.51 (+0.15), TMO: 152.34 (-0.35), STJ: 80.67 (+0.09), HTWR: 57.47 (-0.17), XRAY: 63.74 (+0.35), NUVA: 61.57 (+0.75), FEIC: 106.79 (+0.01)
Cardiovascular Systems Seeks Device Approval in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 7:49AM CDT
On receiving the approval, Japan will become the first international market to offer a product of Cardiovascular Systems (CSII).
HCM: 13.35 (-0.41), CSII: 19.32 (-0.30), GWPH: 96.35 (+1.52), NUVA: 61.57 (+0.75)
Zimmer Biomet Poised on LDR Inclusion, Product Launches
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 8:12AM CDT
On Jul 4, 2016, we issued an updated research report on Zimmer Biomet Holdings, Inc. (ZBH).
BSX: 23.77 (-0.13), ICUI: 115.74 (+0.74), ZBH: 125.08 (+0.19), NUVA: 61.57 (+0.75)
5 Medtech Stocks to Watch Out for in 2H16
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 3:30PM CDT
The global Medtech industry is expected to grow at a CAGR of 4.1% to reach a sales value of $477.5 billion in 2020.
IART: 80.50 (-0.95), MASI: 52.45 (+0.12), LNTH: 4.84 (+0.19), LH: 135.55 (+0.25), NUVA: 61.57 (+0.75)
Abaxis: Growth on Test Menu Expansion; Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 10:38AM CDT
Abaxis (ABAX) has been working on expanding its portfolio of rapid test menu over the recent past.
BSX: 23.77 (-0.13), ICUI: 115.74 (+0.74), ABAX: 52.00 (+1.05), NUVA: 61.57 (+0.75)
NuVasive (NUVA) at 52-Week High on Strategic Initiatives
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 8:03AM CDT
Currently, NuVasive (NUVA) expects its international business to grow by 38% in 2016, at CER.
BSX: 23.77 (-0.13), ICUI: 115.74 (+0.74), GWPH: 96.35 (+1.52), NUVA: 61.57 (+0.75)
NuVasive Completes Acquistion of Biotronic NeuroNetwork
Marketwire Canada - Tue Jul 05, 6:00AM CDT
SAN DIEGO, CA--(Marketwired - July 05, 2016) - NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery, today announced that it has successfully completed the previously announced acquisition of Biotronic NeuroNetwork ("Biotronic"
, a provider of intraoperative neurophysiological monitoring services.
NUVA: 61.57 (+0.75)
Baxter International: Health Canada Okays AMIA APD System
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 7:27AM CDT
Baxter International Inc. (BAX) is forging ahead with its expansion plans in Canada with the launch of AMIA Automated Peritoneal Dialysis (APD) System.
BSX: 23.77 (-0.13), ICUI: 115.74 (+0.74), BAX: 46.49 (-0.16), NUVA: 61.57 (+0.75)
Medtronic Positive on HeartWare Buy, Covidien Synergies
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 7:25AM CDT
On Jun 28, 2016, we issued an updated research report on Medtronic plc (MDT).
ICUI: 115.74 (+0.74), MDT: 88.51 (+0.15), LMAT: 13.64 (-0.06), NUVA: 61.57 (+0.75)
Bruker Poised on Product Launches amid Near-Term Risks
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 7:12AM CDT
On Jun 29, we issued an updated research report on Bruker Corporation (BRKR).
ICUI: 115.74 (+0.74), LMAT: 13.64 (-0.06), BRKR: 24.35 (+0.67), NUVA: 61.57 (+0.75)
Watch for NuVasive to Potentially Pullback After Gaining 1.73% Yesterday
Comtex SmarTrend(R) - Tue Jun 28, 1:41PM CDT
NuVasive (NASDAQ:NUVA) traded in a range yesterday that spanned from a low of $57.79 to a high of $59.20. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $59.03 on volume of 351,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NUVA: 61.57 (+0.75)
NuVasive, Inc. (NUVA) - Product Pipeline Analysis, Update and Research: Radiant Insights
GlobeNewswire - Mon Jun 27, 4:34AM CDT
NuVasive, Inc. (NuVasive) is a medical device company which offers an extensive selection of minimally-disruptive surgical products and procedurally-integrated solutions for spine. The company's product portfolio encompasses surgical procedures including transforaminal lumbar interbody fusion (TLIF); posterior lumbar interbody fusion (PLIF); posterior cervical fusion; anterior cervical discectomy and fusion; extreme lateral interbody fusion corpectomy ; and anterior lumbar interbody fusion. Its TLIF nad PLIF are based on maximum access surgery (MAS), a minimally-disruptive surgical platform. NuVasive also offers nerve monitoring systems, and cellular allograft as a bone graft substitute in spinal fusion surgery.
NUVA: 61.57 (+0.75)
32.4% Return Seen to Date on SmarTrend NuVasive Call (NUVA)
Comtex SmarTrend(R) - Fri Jun 24, 1:07PM CDT
SmarTrend identified an Uptrend for NuVasive (NASDAQ:NUVA) on March 4th, 2016 at $43.48. In approximately 4 months, NuVasive has returned 32.38% as of today's recent price of $57.56.
NUVA: 61.57 (+0.75)
What Investors are Making of These Healthcare Stocks? - Antares Pharma, Globus Medical, NuVasive, and Insulet
PR Newswire - Fri Jun 24, 6:49AM CDT
Since the financial crisis, the Healthcare sector has proven to be defensive against market downturns, continuing to present opportunities for growth. Today's featured companies on Stock-Callers.com belong in this arena: Antares Pharma Inc. (NASDAQ: ATRS), Globus Medical Inc. (NYSE: GMED), NuVasive Inc. (NASDAQ: NUVA), and Insulet Corp. (NASDAQ: PODD). Learn more about these stocks and receive your complimentary trade alerts at:
PODD: 32.11 (unch), GMED: 24.82 (-0.05), NUVA: 61.57 (+0.75), ATRS: 1.06 (+0.03)
Walgreen Boots Hopeful on Rite Aid Buyout amid Margin Woes
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:26AM CDT
On Jun 22, 2016, we issued an updated research report on Walgreens Boots Alliance, Inc. (WBA).
WBA: 82.01 (+0.21), LMAT: 13.64 (-0.06), STJ: 80.67 (+0.09), NUVA: 61.57 (+0.75)
Hill-Rom Introduces VisiVest, First Connected Airways System
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:19AM CDT
Hill-Rom Holdings, Inc. (HRC) recently launched VisiVest System, the world's first wirelessly connected airway clearance system.
ICUI: 115.74 (+0.74), LMAT: 13.64 (-0.06), NUVA: 61.57 (+0.75), HRC: 51.04 (-0.33)
Genomic Health to Offer Epic Science's AR-V7 test, Shares Up
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:28AM CDT
The availability of the AR-V7 serves as a further development to Genomic Health's (GHDX) recently launched Oncotype SEQ Liquid Select, a next-generation, liquid biopsy test.
ICUI: 115.74 (+0.74), GWPH: 96.35 (+1.52), NUVA: 61.57 (+0.75), GHDX: 27.91 (-0.21)
Walgreen Boots: Q3 a Mixed Bag, Achieves $1B in Synergy
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:09AM CDT
In Jun 2016, Walgreens Boots (WBA) was successful in achieving its target of at least $1 billion in combined net synergies from the Alliance Boots deal in fiscal 2016.
ICUI: 115.74 (+0.74), WBA: 82.01 (+0.21), GWPH: 96.35 (+1.52), NUVA: 61.57 (+0.75)
Henry Schein Rides High on Strategic Buyouts, Price Hurts
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:58AM CDT
Henry Schein's (HSIC) latest acquisition development includes the completion of its takeover of 50% interest in J Morita's subsidiary, One Piece Corp.
BSX: 23.77 (-0.13), ICUI: 115.74 (+0.74), HSIC: 181.78 (+1.06), NUVA: 61.57 (+0.75)
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 42.12 (+0.23), JNJ: 122.93 (+0.08), ZBH: 125.08 (+0.19), LDRH: 37.00 (+0.03), MDT: 88.51 (+0.15), TMO: 152.34 (-0.35), STJ: 80.67 (+0.09), HTWR: 57.47 (-0.17), XRAY: 63.74 (+0.35), NUVA: 61.57 (+0.75), FEIC: 106.79 (+0.01)
Cardiovascular Systems Seeks Device Approval in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 7:49AM CDT
On receiving the approval, Japan will become the first international market to offer a product of Cardiovascular Systems (CSII).
HCM: 13.35 (-0.41), CSII: 19.32 (-0.30), GWPH: 96.35 (+1.52), NUVA: 61.57 (+0.75)
Zimmer Biomet Poised on LDR Inclusion, Product Launches
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 8:12AM CDT
On Jul 4, 2016, we issued an updated research report on Zimmer Biomet Holdings, Inc. (ZBH).
BSX: 23.77 (-0.13), ICUI: 115.74 (+0.74), ZBH: 125.08 (+0.19), NUVA: 61.57 (+0.75)
5 Medtech Stocks to Watch Out for in 2H16
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 3:30PM CDT
The global Medtech industry is expected to grow at a CAGR of 4.1% to reach a sales value of $477.5 billion in 2020.
IART: 80.50 (-0.95), MASI: 52.45 (+0.12), LNTH: 4.84 (+0.19), LH: 135.55 (+0.25), NUVA: 61.57 (+0.75)
Abaxis: Growth on Test Menu Expansion; Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 10:38AM CDT
Abaxis (ABAX) has been working on expanding its portfolio of rapid test menu over the recent past.
BSX: 23.77 (-0.13), ICUI: 115.74 (+0.74), ABAX: 52.00 (+1.05), NUVA: 61.57 (+0.75)
NuVasive (NUVA) at 52-Week High on Strategic Initiatives
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 8:03AM CDT
Currently, NuVasive (NUVA) expects its international business to grow by 38% in 2016, at CER.
BSX: 23.77 (-0.13), ICUI: 115.74 (+0.74), GWPH: 96.35 (+1.52), NUVA: 61.57 (+0.75)
NuVasive Completes Acquistion of Biotronic NeuroNetwork
Marketwire Canada - Tue Jul 05, 6:00AM CDT
SAN DIEGO, CA--(Marketwired - July 05, 2016) - NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery, today announced that it has successfully completed the previously announced acquisition of Biotronic NeuroNetwork ("Biotronic"
, a provider of intraoperative neurophysiological monitoring services. NUVA: 61.57 (+0.75)
Baxter International: Health Canada Okays AMIA APD System
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 7:27AM CDT
Baxter International Inc. (BAX) is forging ahead with its expansion plans in Canada with the launch of AMIA Automated Peritoneal Dialysis (APD) System.
BSX: 23.77 (-0.13), ICUI: 115.74 (+0.74), BAX: 46.49 (-0.16), NUVA: 61.57 (+0.75)
Medtronic Positive on HeartWare Buy, Covidien Synergies
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 7:25AM CDT
On Jun 28, 2016, we issued an updated research report on Medtronic plc (MDT).
ICUI: 115.74 (+0.74), MDT: 88.51 (+0.15), LMAT: 13.64 (-0.06), NUVA: 61.57 (+0.75)
Bruker Poised on Product Launches amid Near-Term Risks
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 7:12AM CDT
On Jun 29, we issued an updated research report on Bruker Corporation (BRKR).
ICUI: 115.74 (+0.74), LMAT: 13.64 (-0.06), BRKR: 24.35 (+0.67), NUVA: 61.57 (+0.75)
Watch for NuVasive to Potentially Pullback After Gaining 1.73% Yesterday
Comtex SmarTrend(R) - Tue Jun 28, 1:41PM CDT
NuVasive (NASDAQ:NUVA) traded in a range yesterday that spanned from a low of $57.79 to a high of $59.20. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $59.03 on volume of 351,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NUVA: 61.57 (+0.75)
NuVasive, Inc. (NUVA) - Product Pipeline Analysis, Update and Research: Radiant Insights
GlobeNewswire - Mon Jun 27, 4:34AM CDT
NuVasive, Inc. (NuVasive) is a medical device company which offers an extensive selection of minimally-disruptive surgical products and procedurally-integrated solutions for spine. The company's product portfolio encompasses surgical procedures including transforaminal lumbar interbody fusion (TLIF); posterior lumbar interbody fusion (PLIF); posterior cervical fusion; anterior cervical discectomy and fusion; extreme lateral interbody fusion corpectomy ; and anterior lumbar interbody fusion. Its TLIF nad PLIF are based on maximum access surgery (MAS), a minimally-disruptive surgical platform. NuVasive also offers nerve monitoring systems, and cellular allograft as a bone graft substitute in spinal fusion surgery.
NUVA: 61.57 (+0.75)
32.4% Return Seen to Date on SmarTrend NuVasive Call (NUVA)
Comtex SmarTrend(R) - Fri Jun 24, 1:07PM CDT
SmarTrend identified an Uptrend for NuVasive (NASDAQ:NUVA) on March 4th, 2016 at $43.48. In approximately 4 months, NuVasive has returned 32.38% as of today's recent price of $57.56.
NUVA: 61.57 (+0.75)
What Investors are Making of These Healthcare Stocks? - Antares Pharma, Globus Medical, NuVasive, and Insulet
PR Newswire - Fri Jun 24, 6:49AM CDT
Since the financial crisis, the Healthcare sector has proven to be defensive against market downturns, continuing to present opportunities for growth. Today's featured companies on Stock-Callers.com belong in this arena: Antares Pharma Inc. (NASDAQ: ATRS), Globus Medical Inc. (NYSE: GMED), NuVasive Inc. (NASDAQ: NUVA), and Insulet Corp. (NASDAQ: PODD). Learn more about these stocks and receive your complimentary trade alerts at:
PODD: 32.11 (unch), GMED: 24.82 (-0.05), NUVA: 61.57 (+0.75), ATRS: 1.06 (+0.03)
Walgreen Boots Hopeful on Rite Aid Buyout amid Margin Woes
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:26AM CDT
On Jun 22, 2016, we issued an updated research report on Walgreens Boots Alliance, Inc. (WBA).
WBA: 82.01 (+0.21), LMAT: 13.64 (-0.06), STJ: 80.67 (+0.09), NUVA: 61.57 (+0.75)
Hill-Rom Introduces VisiVest, First Connected Airways System
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:19AM CDT
Hill-Rom Holdings, Inc. (HRC) recently launched VisiVest System, the world's first wirelessly connected airway clearance system.
ICUI: 115.74 (+0.74), LMAT: 13.64 (-0.06), NUVA: 61.57 (+0.75), HRC: 51.04 (-0.33)
